AI-Powered Stroke Platform Triples Functional Independence, Cuts Treatment Times

OXFORD, UK – November 10, 2025 – A groundbreaking AI-powered imaging solution is transforming stroke care, dramatically improving patient outcomes and slashing crucial treatment times, according to newly published research and confirmed by the company. Brainomix’s 360 Stroke platform, born from research at the University of Oxford, is demonstrating an unprecedented ability to identify and treat stroke patients, potentially saving lives and minimizing long-term disability.

From Lab to Lifesaver

Founded in 2010 as a spin-out from the University of Oxford’s preclinical stroke lab, Brainomix has rapidly become a leader in AI-driven neuroimaging. The company’s 360 Stroke platform utilizes advanced algorithms to analyze CT scans, providing clinicians with real-time insights into the extent and nature of brain damage. This allows for faster and more accurate diagnoses, enabling quicker decisions regarding treatment options such as thrombolysis or mechanical thrombectomy.

The platform's journey from academic research to clinical application highlights the growing potential of AI in healthcare. What began as a project within the Nuffield Department of Clinical Neurosciences has evolved into a widely adopted tool used in hundreds of hospitals worldwide, and is now deployed across England’s National Health Service (NHS).

Triple the Independence: Dramatic Improvements in Patient Outcomes

New data reveals a significant impact on patient functional independence. A recent study showed that the use of Brainomix’s 360 Stroke platform tripled the number of stroke patients achieving functional independence (defined as a modified Rankin Scale score of 0-2 at 90 days), increasing from 16% to 48%. This represents a remarkable improvement, suggesting a significant reduction in long-term disability among stroke survivors.

“The impact on functional outcomes is truly remarkable,” said a stroke specialist who wished to remain anonymous. “We are seeing patients who previously would have been left with significant impairments now regaining a much greater level of independence. It's changing lives.”

Speeding Up Critical Treatment

Time is brain when it comes to stroke. Every minute counts, as approximately 2 million brain cells are lost per minute during an ischemic stroke. Brainomix’s platform is demonstrably reducing the time it takes to diagnose and treat stroke patients. Research indicates that implementation of the platform has reduced door-in-door-out (DIDO) times – the time from hospital arrival to treatment initiation – by over an hour in some cases, and nearly 50 minutes on average in a large-scale evaluation.

Furthermore, the NHS deployment of Brainomix 360 Stroke across England has shortened the overall time to treatment for suspected stroke patients from 140 minutes to 79 minutes. This accelerated timeline is crucial in maximizing the effectiveness of time-sensitive treatments like thrombolysis and mechanical thrombectomy.

Competitive Landscape & Technological Edge

The AI-powered stroke imaging market is becoming increasingly crowded, with several companies vying for market share. Key competitors include Viz.ai, Aidoc, and RapidAI. However, Brainomix distinguishes itself through its comprehensive approach and robust clinical evidence.

“Brainomix has established a strong position in the market through its commitment to innovation and clinical validation,” explained an industry analyst who requested anonymity. “Their e-ASPECTS tool, which automates the ASPECTS scoring system, is a key differentiator, providing clinicians with a clear and concise assessment of the extent of brain damage.”

The company’s recent FDA clearance for a novel feature enabling ischemic core volume assessment from non-contrast CT scans further expands its capabilities, offering a valuable tool for centers with limited access to advanced imaging modalities. Comparative analyses have also suggested that Brainomix 360 Stroke exhibits higher sensitivity for more distal occlusions than some competing solutions, alongside unique association with perfusion deficits and neurological function scores.

Cost-Effectiveness & Wider Adoption

Beyond improved patient outcomes and reduced treatment times, Brainomix’s 360 Stroke platform also demonstrates significant cost-effectiveness. A York University analysis determined that the implementation of the platform yields an incremental cost-effectiveness ratio (ICER) of £5,165, well below the £20,000 threshold considered acceptable by the UK’s NHS.

This economic benefit, coupled with the clinical advantages, is driving wider adoption of the platform both within the UK and internationally. The company is actively expanding its presence in new markets, seeking to bring the benefits of AI-powered stroke care to patients around the world.

Looking Ahead

Brainomix is not resting on its laurels. The company is actively investing in research and development, seeking to expand its AI-powered imaging platforms beyond stroke into other therapeutic areas, including lung disease and cancer. They are also exploring the use of machine learning to predict stroke risk and personalize treatment strategies.

“We believe that AI has the potential to revolutionize healthcare,” stated a company spokesperson. “Our mission is to empower clinicians with the tools they need to deliver the best possible care to their patients.”

The journey of Brainomix from academic research to clinical impact is a testament to the power of innovation and the potential of AI to transform healthcare. As the company continues to push the boundaries of what’s possible, it is poised to play a leading role in shaping the future of stroke care and beyond.